Date published: 2026-7-8

1-800-457-3801

SCBT Portrait Logo
Seach Input

CYYR1 CRISPR/Cas9 KO Plasmid (m): sc-432449

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • CYYR1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYYR1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    CYYR1 CRISPR/Cas9 KO Plasmid (m)

    sc-432449
    20 µg
    $397.00

    Overview

    Cyyr1 encodes cysteine and tyrosine rich 1 (CYYR1), a conserved protein that has been implicated in cellular stress responses and regulatory signaling at the interface of cytoskeletal organization and transcriptional control. In mouse models and cell systems, CYYR1 expression is responsive to inflammatory cues and has been linked to pathways governing epithelial and immune cell behavior, including remodeling processes that influence adhesion and migration. Although its molecular partners remain incompletely defined, CYYR1 has been associated with context-dependent regulation of growth and differentiation programs. Dysregulated CYyr1 expression has been reported in settings relevant to inflammation-associated tissue remodeling and oncogenic phenotypes, supporting its utility as a research target for mechanistic studies.

    CYYR1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cyyr1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cyyr1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cyyr1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYYR1 protein expression.

    This CRISPR knockout system enables efficient generation of Cyyr1-deficient cell models for investigation of CYYR1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Cyyr1 exon(s) critical for CYYR1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Cyyr1 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by CYYR1 CRISPR/Cas9 KO Plasmid (m) and CYYR1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cyyr1 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by CYYR1 HDR Plasmid (m) and CYYR1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cyyr1 homology arms to support homology-directed repair at defined Cyyr1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.